Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer

Oncologist. 2021 Jun 21. doi: 10.1002/onco.13866. Online ahead of print.NO ABSTRACTPMID:34152031 | DOI:10.1002/onco.13866

Source: The Oncologist - June 21, 2021 Category: Cancer & Oncology Source Type: research